EHEdward S. Horton

Edward S. Horton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Edward S. Horton has a total of 76 co-authors. Here are the top co-authors by number of shared publications:

  • Andres Cardenas

    Stanford University

    3 shared publications
  • Antonia M. Calafat

    Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA

    3 shared publications
  • Diane R. Gold

    Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA

    3 shared publications
  • Emily Oken

    Division of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Medical School, and Harvard Pilgrim Health Care Institute, Boston, MA, USA

    3 shared publications
  • Ken P. Kleinman

    Department of Biostatistics, School of Public Health and Human Sciences, University of Massachusetts Amherst, Amherst, MA, USA

    3 shared publications
  • Marie-France Hivert

    Division of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Medical School, and Harvard Pilgrim Health Care Institute, Boston, MA, USA

    3 shared publications

Latest Publications

  • Open Access

    Temporal trends of concentrations of per- and polyfluoroalkyl substances among adults with overweight and obesity in the United States: Results from the Diabetes Prevention Program and NHANES

    by Pi-I D. Lin, Andres Cardenas, Russ Hauser, Diane R. Gold, Ken P. Kleinman, Marie-France Hivert, Antonia M. Calafat, Thomas F. Webster, Edward S. Horton, Emily Oken


  • Open Access

    Per- and polyfluoroalkyl substances and kidney function: Follow-up results from the Diabetes Prevention Program trial

    by Pi-I D. Lin, Andres Cardenas, Russ Hauser, Diane R. Gold, Ken P. Kleinman, Marie-France Hivert, Antonia M. Calafat, Thomas F. Webster, Edward S. Horton, Emily Oken


  • Open Access

    Per- and polyfluoroalkyl substances and blood pressure in pre-diabetic adults—cross-sectional and longitudinal analyses of the diabetes prevention program outcomes study

    by Pi-I D. Lin, Andres Cardenas, Russ Hauser, Diane R. Gold, Ken P. Kleinman, Marie-France Hivert, Antonia M. Calafat, Thomas F. Webster, Edward S. Horton, Emily Oken


  • Open Access

    Long Term Effect of Intensive Lifestyle Intervention on Cerebral Blood Flow

    by Mark A. Espeland, Jose A. Luchsinger, Rebecca H. Neiberg, Owen Carmichael, Paul J. Laurienti, Xavier Pi‐Sunyer, Rena R. Wing, Delilah Cook, Edward Horton, Ramon Casanova, et al.

    Objectives: To determine whether long‐term behavioral intervention targeting weight loss through increased physical activity and reduced caloric intake would alter cerebral blood flow ( CBF ) in individuals with type 2 diabetes mellitus. Design: Postrandomization assessment of CBF. Setting: Action for Health in Diabetes multicenter randomized controlled clinical trial. Participants: Individuals with type 2 diabetes mellitus who were overweight or obese and aged 45 to 76 (N = 310). Interventions: A multidomain intensive lifestyle intervention ( ILI ) to induce weight loss and increase physical activity for 8 to 11 years or diabetes support and education ( DSE ), a control condition. Measurements: Participants underwent cognitive assessment and standardized brain magnetic resonance imaging ( MRI ) (3.0 Tesla) to assess CBF an average of 10.4 years after randomization. Results: Weight changes from baseline to time of MRI averaged −6.2% for ILI and −2.8% for DSE ( P < .001), and increases in self‐reported moderate or intense physical activity averaged 444.3 kcal/wk for ILI and 114.8 kcal/wk for DSE ( P = .03). Overall mean CBF was 6% greater for ILI than DSE ( P = .04), with the largest mean differences between ILI and DSE in the limbic region (3.39 mL /100 g per minute, 95% confidence interval ( CI ) = 0.07–6.70 mL /100 g per minute) and occipital lobes (3.52 mL /100 g per minute, 95% CI = 0.20–6.84 mL /100 g per minute). In ILI , greater CBF was associated with greater decreases in weight and greater increases in physical activity. The relationship between CBF and scores on a composite measure of cognitive function varied between intervention groups ( P = .02). Conclusions: Long‐term weight loss intervention in overweight and obese adults with type 2 diabetes mellitus is associated with greater CBF .


  • Open Access

    The Effect of Intentional Weight Loss on Fracture Risk in Persons With Diabetes: Results From the Look AHEAD Randomized Clinical Trial

    by Karen C Johnson, George A Bray, Lawrence J Cheskin, Jeanne M Clark, Caitlin M Egan, John P Foreyt, Katelyn R Garcia, Stephen Glasser, Frank L Greenway, Edward W Gregg, et al.

    Intentional weight loss is an important treatment option for overweight persons with type 2 diabetes mellitus (DM), but the effects on long‐term fracture risk are not known. The purpose of this Look AHEAD analysis was to evaluate whether long‐term intentional weight loss would increase fracture risk in overweight or obese persons with DM. Look AHEAD is a multicenter, randomized clinical trial. Recruitment began in August 2001 and follow‐up continued for a median of 11.3 years at 16 academic centers. A total of 5145 persons aged 45 to 76 years with DM were randomized to either an intensive lifestyle intervention (ILI) with reduced calorie consumption and increased physical activity designed to achieve and maintain ≥7% weight loss or to diabetes support and education intervention (DSE). Incident fractures were ascertained every 6 months by self‐report and confirmed with central adjudication of medical records. The baseline mean age of participants was 59 years, 60% were women, 63% were white, and the mean BMI was 36 kg/m2. Weight loss over the intervention period (median 9.6 years) was 6.0% in ILI and 3.5% in DSE. A total of 731 participants had a confirmed incident fracture (358 in DSE versus 373 in ILI). There were no statistically significant differences in incident total or hip fracture rates between the ILI and DSE groups. However, compared to the DSE group, the ILI group had a statistically significant 39% increased risk of a frailty fracture (HR 1.39; 95% CI, 1.02 to 1.89). An intensive lifestyle intervention resulting in long‐term weight loss in overweight/obese adults with DM was not associated with an overall increased risk of incident fracture but may be associated with an increased risk of frailty fracture. When intentional weight loss is planned, consideration of bone preservation and fracture prevention is warranted. © 2017 American Society for Bone and Mineral Research.


  • Open Access

    Young Hispanics at risk of type 2 diabetes display endothelial activation, subclinical inflammation and alterations of coagulation and fibrinolysis

    by Carlos O Mendivil, Ludivina Robles-Osorio, Edward S Horton, Osama Hamdy, Augusto Enrique Caballero

    Background: Hispanics have a high rate of diabetes that exposes them to an increased risk of cardiovascular disease. We hypothesized that many of the pathophysiological mechanisms that cause atherosclerotic disease may be present in young Hispanics who do not have clinical diabetes but are at increased risk of developing it. Methods: We studied 36 young Hispanic adults without diabetes (ages 18–40). Seventeen participants were at increased risk of developing type 2 diabetes given by overweight and a family history of diabetes on one or both parents (at risk group). Nineteen participants with normal body-mass index and no parental history of diabetes constituted the control group. We measured and compared plasma markers of endothelial dysfunction, disturbed coagulation and fibrinolysis, subclinical inflammation and adipose tissue dysfunction in the at risk and control groups. Results: Participants at risk of diabetes were more insulin-resistant according to different indicators, and had significantly higher levels of soluble intercellular adhesion molecule-1 (sICAM-1), tissue plasminogen activator (tPA), inhibitor of plasminogen activator-1 (PAi-1), high sensitivity C-reactive protein and free fatty acids, signaling the presence of multiple proatherogenic alterations despite the absence of overt diabetes. Levels of the prothrombotic molecule PAi-1 were most elevated in participants who were not only at risk of diabetes by the study definition, but also abdominally obese. Conclusions: Young adult Hispanics at risk of type 2 diabetes but without overt disease already bear considerably high levels of markers reflecting processes that lead to the development of atherosclerotic cardiovascular disease.


  • Open Access

    Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database

    by Edward S. Horton, Cheryl Silberman, Keith L. Davis, Rachele Berria

    OBJECTIVE: Weight loss in patients with type 2 diabetes can improve glycemic control, lower blood pressure, and improve dyslipidemia. Glucagon-like peptide (GLP-1) receptor agonists are associated with weight loss and have potentially beneficial effects on cardiovascular risk biomarkers; however, there is limited information to indicate whether these effects remain outside of clinical trials. RESEARCH DESIGN AND METHODS: Medical records from the General Electric Centricity research database were analyzed retrospectively to evaluate the relationship between weight loss and glycemic control and changes in blood pressure and lipids in patients with type 2 diabetes initiating therapy with exenatide, sitagliptin, or insulin. Baseline and follow-up (90–365 days after the index date) for weight, A1C, fasting blood glucose (FBG), blood pressure, triglycerides, and LDL, HDL, and total cholesterol were assessed. RESULTS: A total of 6,280, 5,861, and 32,398 patients receiving exenatide, sitagliptin, or insulin, respectively, were included in the analysis. Exenatide-treated patients lost a mean ± SD of 3.0 ± 7.33 kg, sitagliptin-treated patients lost 1.1 ± 5.39 kg, and insulin-treated patients gained 0.6 ± 9.49 kg. There was a significant association between weight loss and a reduction in A1C and FBG with exenatide only and a reduction in blood pressure for all therapies. Weight loss was associated with some improvements in lipids, primarily in the GLP-1 receptor agonist group, with little association in the insulin group. CONCLUSIONS: Weight reduction with GLP-1 receptor agonists was associated with a shift toward a more favorable cardiovascular risk profile. Outcome trials are needed to determine whether improvement in biomarkers translates into a reduction in cardiovascular events in patients with type 2 diabetes.